etoposide has been researched along with Hepatic Veno Occlusive Disease in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (35.71) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lavolé, J; Le Goff, M; Mallet, V; Oudjit, A; Sogni, P | 1 |
| Fornecker, LM; Guffroy, A; Korganow, AS; Martin, M; Meyer, A | 1 |
| Bagatell, R; Bunin, NJ; Desai, AV; Grupp, SA; Heneghan, MB; Li, Y; Seif, AE | 1 |
| Amoroso, L; Benhamou, E; Cacchione, A; Couanet, DV; Hartmann, O; LeMaitre, A; Simonnard, N | 1 |
| Biron, P; Ghesquières, H; Labidi, SI; Nicolas, EV; Sebban, C | 1 |
| Annaloro, C; Deliliers, GL; Ibatici, A; Nicolini, A; Pozzoli, E; Robbiolo, L; Salerno, F | 1 |
| Cupelli, L; de la Rubia, J; Jarque, I; Jiménez, C; Lorenzo, I; Martín, G; Martínez, JA; Puig, N; Remigia, MJ; Sanz, GF; Sanz, J; Sanz, MA | 1 |
| Kabisch, H; Kalhs, P; Krüger, W; Lechner, K; Peters, S; Stockschläder, M; Zander, A; Zeller, W | 1 |
| Akiyama, H; Kanda, Y; Onozawa, Y; Sakamaki, H; Sasaki, T; Takamoto, S; Tanikawa, S | 1 |
| Davidson, TG; Devine, SM; Dix, SP; Geller, RB; Gilmore, CE; Heffner, LT; Hillyer, CD; Holland, HK; Jerkunica, I; Lin, LS; Mullins, RE; Saral, R; Wingard, JR; Winton, EF; York, RC | 1 |
| Becker, AT; Gruppo, RA; Harris, RE; Hashmi, R; Morris, CL; Morris, JD; Sambrano, JE | 1 |
| Aulagner, G; Bertrand, Y; Bleyzac, N; Dai, Q; Galambrun, C; Janoly, A; Jelliffe, RW; Magron, P; Maire, P; Martin, P; Souillet, G | 1 |
| De Giorgi, U; Marangolo, M; Papiani, G; Rosti, G | 1 |
| Bierman, PJ; Dennison, JD; Gordon, BG; Klassen, L; Kumar, PP; McGuire, TR; Reed, EC; Sanger, WG; Vaughan, WP; Warkentin, PI | 1 |
2 review(s) available for etoposide and Hepatic Veno Occlusive Disease
| Article | Year |
|---|---|
[Sinusoidal obstruction syndrome after BeAM conditioning regiment for autologous stem cell transplantation: Imputability of bendamustine? Report of two cases and literature review].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Autologous | 2018 |
The status of high-dose chemotherapy with hematopoietic stem cell transplantation in germ cell tumor patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Etoposide; Europe; Forecasting; Gastrointestinal Diseases; Germinoma; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Ifosfamide; Kidney Diseases; Male; Multicenter Studies as Topic; Neoplasms, Second Primary; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Salvage Therapy; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2002 |
2 trial(s) available for etoposide and Hepatic Veno Occlusive Disease
| Article | Year |
|---|---|
Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Male; Melphalan; Middle Aged; Morbidity; Mortality; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous | 2006 |
Etoposide with/without G-CSF with busulfan and cyclophosphamide as conditioning for bone marrow transplantation. The BMT Team.
Topics: Adolescent; Adult; Bone Marrow; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Drug Administration Schedule; Drug Synergism; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hepatic Veno-Occlusive Disease; Humans; Hyperbilirubinemia; Immunologic Factors; Leukemia, Myeloid; Leukopenia; Male; Middle Aged; Premedication; Salvage Therapy | 1996 |
10 other study(ies) available for etoposide and Hepatic Veno Occlusive Disease
| Article | Year |
|---|---|
Abdominal computed tomography angiography in post-transplantation sinusoidal obstruction syndrome associated with R-DHAOX/BEAM toxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Computed Tomography Angiography; Cytarabine; Dexamethasone; Etoposide; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Organoplatinum Compounds; Syndrome | 2018 |
Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Child; Child, Preschool; Cohort Studies; Etoposide; Female; Hepatic Veno-Occlusive Disease; Humans; Hypertension, Pulmonary; Infant; Kidney Diseases; Male; Melphalan; Mucositis; Myeloablative Agonists; Neuroblastoma; Pancytopenia; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Young Adult | 2016 |
Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen.
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Busulfan; Carboplatin; Child; Child, Preschool; Clonazepam; Etoposide; Female; Hepatic Veno-Occlusive Disease; Humans; Infant; Male; Retrospective Studies; Risk Factors; Sarcoma; Seizures; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2008 |
Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Etoposide; Hepatic Veno-Occlusive Disease; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous | 2008 |
Four-year survival after trans-jugular intrahepatic porto-systemic shunt for veno-occlusive disease following autologous bone marrow transplantation.
Topics: Adult; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Hemodynamics; Hepatic Veno-Occlusive Disease; Humans; Jugular Veins; Lymphoma, Large-Cell, Anaplastic; Male; Peripheral Blood Stem Cell Transplantation; Portasystemic Shunt, Surgical; Remission Induction; Thrombophilia; Transplantation Conditioning; Transplantation, Autologous | 2004 |
Intravenous pentoxifylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients.
Topics: Adolescent; Adult; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Child; Cyclophosphamide; Etoposide; Gastrointestinal Diseases; Hepatic Veno-Occlusive Disease; Humans; Hyperbilirubinemia; Incidence; Infusions, Intravenous; Kidney Diseases; Middle Aged; Pentoxifylline; Survival Analysis; Treatment Outcome; Tumor Necrosis Factor-alpha; Whole-Body Irradiation | 1993 |
Association of busulfan area under the curve with veno-occlusive disease following BMT.
Topics: Adolescent; Adult; Aged; Bone Marrow Transplantation; Busulfan; Circadian Rhythm; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Hepatic Veno-Occlusive Disease; Humans; Male; Middle Aged; Retrospective Studies; Risk | 1996 |
Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation.
Topics: Adolescent; Adult; Anticoagulants; Antithrombin III; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Infant; Life Tables; Male; Multiple Organ Failure; Neoplasms; Severity of Illness Index; Survival Analysis; Thrombophilia; Transplantation Conditioning; Treatment Outcome | 1997 |
Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
Topics: Adolescent; Alkylating Agents; Area Under Curve; Bayes Theorem; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Genetic Diseases, Inborn; Graft Survival; Hematologic Neoplasms; Hepatic Veno-Occlusive Disease; Humans; Incidence; Infant; Life Tables; Male; Melphalan; Prospective Studies; Severe Combined Immunodeficiency; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2001 |
Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Humans; Immunosuppressive Agents; Incidence; Leukemia; Middle Aged; Time Factors; Transplantation, Homologous | 1991 |